 |
| HLA-B (alpha)-β2MG with bound peptide |
|
major histocompatibility complex (human), class I, B58
|
| Alleles |
*5801, *5802 |
| Structure (See HLA-B) |
| Shared data |
| Locus |
chr.6 6p21.31 |
HLA-B58 (B58) is an HLA-B serotype. B58 is a split antigen from the B17 broad antigen, the sister serotype B57.[1] The serotype identifies the more common HLA-B*58 gene products.[2] (For terminology help see: HLA-serotype tutorial) B*5801 is associated with allopurinol induced inflammatory necrotic skin disease.
[edit] Serotype
B58 and B17 serotype recognition of some more common HLA B*58 alleles[3]
| B*58 |
B58 |
B17 |
Sample |
| allele |
% |
% |
size (N) |
| *5801 |
79 |
4 |
2096 |
| *5802 |
72 |
3 |
837 |
[edit] Allele distribution
HLA B*5801 frequencies
|
|
freq |
| ref. |
Population |
(%) |
| [4] |
Cameroon Pygmy Baka |
15.0 |
| [4] |
India Khandesh Pawra |
15.0 |
| [4] |
Cameroon Sawa |
11.5 |
| [4] |
Taiwan Hakka |
10.9 |
| [4] |
Kenya Nandi |
10.0 |
| [4] |
India West Bhils |
9.0 |
| [4] |
China South Han |
8.9 |
| [4] |
China Inner Mongolia |
8.8 |
| [4] |
India North Delhi |
8.8 |
| [4] |
Thailand Northeast |
8.4 |
| [4] |
Guinea Bissau |
7.8 |
| [4] |
Thailand |
7.7 |
| [4] |
India Mumbai Marathas |
7.4 |
| [4] |
India Andhra Pradesh Golla |
7.2 |
| [4] |
Kenya Luo |
7.0 |
| [4] |
Senegal Niokholo Mandenka |
6.9 |
| [4] |
India New Delhi |
6.8 |
| [4] |
Oman |
6.8 |
| [4] |
Russia Tuva (2) |
6.7 |
| [4] |
South Korea (3) |
6.5 |
| [4] |
Italy Sardinia (3) |
6.4 |
| [4] |
Burkina Faso Fulani |
6.1 |
| [4] |
Taiwan Siraya |
5.9 |
| [4] |
India North Hindus |
5.8 |
| [4] |
Burkina Faso Mossi |
5.7 |
| [4] |
Cameroon Yaounde |
5.4 |
| [4] |
Cameroon Bamileke |
5.2 |
| [4] |
Singapore Riau Malay |
5.0 |
| [4] |
Saudi Arabia Guraiat and Hail |
4.6 |
| [4] |
France Corsica |
4.5 |
| [4] |
Sudanese |
4.5 |
| [4] |
Zimbabwe Harare Shona |
4.4 |
| [4] |
Burkina Faso Rimaibe |
4.3 |
| [4] |
Iran Baloch |
4.0 |
| [4] |
South Africian Natal Zulu |
4.0 |
| [4] |
Tunisia |
4.0 |
| [4] |
Uganda Kampala |
4.0 |
| [4] |
Cameroon Beti |
3.7 |
| [4] |
Tunisia Ghannouch |
3.7 |
| [4] |
Taiwan Pazeh |
3.6 |
| [4] |
Tunisia Tunis |
3.4 |
| [4] |
Italy North (1) |
3.3 |
| [4] |
Israel Ashkenazi and Non Ashkenazi Jews |
3.2 |
| [4] |
India West Coast Parsis |
3.0 |
| [4] |
China North Han |
2.9 |
| [4] |
Ivory Coast Akan Adiopodoume |
2.3 |
| [4] |
Mali Bandiagara |
2.2 |
| [4] |
Mexico Zaptotec Oaxaca |
2.2 |
| [4] |
South Africa Natal Tamil |
2.0 |
| [4] |
China Yunnan Nu |
1.9 |
| [4] |
Bulgaria |
1.8 |
| [4] |
China Tibet Autonomous Region Tibetans |
1.6 |
| [4] |
France South East |
1.6 |
| [4] |
Israel Arab Druse |
1.5 |
| [4] |
Czech Republic |
1.4 |
| [4] |
Georgia Tibilisi Georgians |
1.4 |
| [4] |
Jordan Amman |
1.4 |
| [4] |
Morocco Nador Metalsa (berber) |
1.4 |
| [4] |
Croatia |
1.3 |
| [4] |
Romanian |
1.3 |
| [4] |
Spain Eastern Andalusia |
1.2 |
| [4] |
Australian Aborigine Cape York Peninsula |
1.0 |
|
B*5802 |
| [4] |
Cameroon Bamileke |
14.3 |
| [4] |
Kenya Luo |
12.5 |
| [4] |
Cameroon Yaounde |
10.9 |
| [4] |
Cameroon Pygmy Baka |
10.0 |
| [4] |
Cameroon Beti |
9.8 |
| [4] |
Kenya Nandi |
8.5 |
| [4] |
South Africian Natal Zulu |
8.5 |
| [4] |
Cameroon Sawa |
7.7 |
| [4] |
Zimbabwe Harare Shona |
6.4 |
| [4] |
Cape Verde Northwestern Islands |
5.6 |
| [4] |
Uganda Kampala |
4.4 |
| [4] |
Central Africa Republic Mbenzele Pygmy |
4.0 |
| [4] |
Zambia Lusaka |
2.3 |
| [4] |
Iran Baloch |
1.0 |
| [4] |
Tunisia |
1.0 |
[edit] Disease
HLA-B*5801 is involved in allopurinol sensitive drug induced Stevens–Johnson syndrome.[5][6] Allopurinol is a frequent cause of severe cutaneous adverse reactions, including drug-hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis (SJS/TEN).[7] The association with allopurinol sensitivity in JSJ/TEN was extremely strong in Asia, and somewhat less associated in Europeans.[8]
[edit] References
- ^ Ways JP, Coppin HL, Parham P (1985). "The complete primary structure of HLA-Bw58". J. Biol. Chem. 260 (22): 11924–33. PMID 2995352.
- ^ Marsh SG, Albert ED, Bodmer WF et al (2005). "Nomenclature for factors of the HLA system, 2004". Tissue Antigens 65 (4): 301–69. doi:10.1111/j.1399-0039.2005.00379.x. PMID 15787720.
- ^ derived from IMGT/HLA
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn bo bp bq br bs bt bu bv bw bx by Middleton D, Menchaca L, Rood H, Komerofsky R (2003). "New allele frequency database: http://www.allelefrequencies.net". Tissue Antigens 61 (5): 403–7. doi:10.1034/j.1399-0039.2003.00062.x. PMID 12753660.
- ^ Chung WH, Hung SI, Chen YT (August 2007). "Human leukocyte antigens and drug hypersensitivity". Curr Opin Allergy Clin Immunol 7 (4): 317–23. doi:10.1097/ACI.0b013e3282370c5f. PMID 17620823.
- ^ Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W (2009). "Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population". Pharmacogenet Genomics 19 (9): 704–9. doi:10.1097/FPC.0b013e328330a3b8. PMID 19696695.
- ^ Hung SI, Chung WH, Liou LB et al (March 2005). "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol". Proc. Natl. Acad. Sci. U.S.A. 102 (11): 4134–9. doi:10.1073/pnas.0409500102. PMC 554812. PMID 15743917. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=554812.
- ^ Lonjou C, Borot N, Sekula P et al (February 2008). "A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs". Pharmacogenet. Genomics 18 (2): 99–107. doi:10.1097/FPC.0b013e3282f3ef9c. PMID 18192896.
